Poorly differentiated thyroid carcinomas (PDTC) are generally uncommon and represent approximately 1% of all thyroid malignancies^[@R1]^. They originate from follicular thyroid cells and have morphologic and biologic attributes that are intermediate between differentiated (papillary or follicular) and anaplastic (undifferentiated) thyroid carcinoma. The ten-year survival of these patients is 60-70%, significantly worse than well-differentiated carcinomas, but considerably better than anaplastic thyroid carcinomas^[@R1]-[@R3]^.

Historically, the histopathologic criteria used to diagnose PDTC have been a subject of controversy and have lacked a consensus. The Turin criteria for the diagnosis of PDTC were established at a consensus meeting held in 2006 and are the most widely accepted, having recently been adopted by the 2017 edition of the World Health Organization Classification of Tumors of the Endocrine Organs^[@R4],[@R5]^. According to the Turin criteria, PDTC is defined as a tumor with solid, trabecular or insular growth that lacks papillary nuclear features and has at least one of the following: ≥ 3 mitoses per 10 high power fields (HPF), tumor necrosis or convoluted nuclei^[@R4]^. An alternative approach to the diagnosis of PDTC was proposed in a 2006 Memorial Sloan-Kettering Cancer Center (MSKCC) study in which PDTC was defined as any follicular cell-derived, non-anaplastic tumor with ≥ 5 mitoses per 10 HPF and/or necrosis^[@R6]^. The MSKCC criteria are less restrictive and, unlike the Turin criteria, include tumors that have papillary nuclear features and/or follicular architecture. Thus, while predictive of more aggressive biologic behavior, some tumors that meet MSKCC criteria are not exclusively poorly differentiated morphologically.

The overwhelming majority of PDTCs have occurred in adults with a mean patient age of 60 years^[@R4],[@R7]^. PDTCs are exceedingly rare in children and adolescents with existing literature limited mainly to case reports^[@R8]-[@R28]^. The ability to extrapolate data from the literature is limited by the lack of uniform or clear diagnostic criteria, especially in reports that pre-date the publication of the Turin diagnostic criteria in 2007. Regarding the molecular mechanisms underlying PDTC, they have been studied almost exclusively in tumors from adults showing "early" genetic drivers characteristic of well-differentiated thyroid papillary and follicular carcinomas (e.g. *BRAF*, *RAS* mutations, *RET*, *ALK* fusions) and "late" driver mutations (*TERT*, *TP53*) characteristic of anaplastic carcinoma^[@R29]-[@R31]^. It remains unknown whether pediatric PDTC share genetic profiles with adult tumors or have distinct molecular mechanisms.

Here, we report detailed characterization of the clinical, pathologic and molecular features of PDTC in children and adolescents in a multi-institutional series of 6 patients. Our findings indicate that PDTC of childhood and adolescence appears to be a unique entity, distinct from morphologically similar tumors occurring in adults, and characterized by somatic *DICER1* mutations found in most patients, with coexisting germline *DICER1* mutations characteristic of DICER1 syndrome in a minority.

Materials and Methods {#S1}
=====================

Case selection {#S2}
--------------

This study was approved by the Human Studies Protection Office at Washington University, the Institutional Review Board of University of Pittsburgh and the McGill University Health Centre, Montreal. Pathology Department files of Washington University and the University of Pittsburgh, including consults, were searched for cases of PDTC occurring in patients ≤ 21 years of age. One additional case was identified at Vanderbilt University. Cases were included if the histologic features met Turin criteria for the diagnosis of PDTC^[@R4]^. The Turin criteria include the presence of solid/insular/trabecular growth pattern; absence of nuclear features of papillary thyroid carcinoma; and the presence of at least one of the following features: convoluted nuclei, mitotic activity of ≥ 3 mitoses per 10 high power field or tumor necrosis^[@R4]^. Six cases met Turin criteria and were included in the study. Clinical data was retrieved from the electronic medical record.

ThyroSeq v3 targeted NGS assay {#S3}
------------------------------

Targeted next generation sequencing (NGS) analysis of thyroid cancer-related mutations and gene fusions was performed at the University of Pittsburgh Medical Center using a 112-gene ThyroSeq version 3 Genomic Classifier panel. It utilizes tumor DNA and RNA to test for 12,135 single nucleotide variations (SNVs) and insertions/deletions (indels) (COSMIC hotspots) and for more than 150 gene fusions (GF) implicated in thyroid cancer as previously described ^[@R32]^. In brief, manual microdissection of tumor-rich areas and paired normal tissue from unstained slides of formalin-fixed paraffin-embedded tissue was performed under a microscope with hematoxylin and eosin guidance. DNA and mRNA were isolated using MagNa Pure instrument (Roche). NGS libraries were generated using 10 ng DNA and 10 ng RNA using the Ion AmpliSeq Library kit 2.0. The libraries were sequenced on the Ion Proton or Ion GeneStudio S5 System (Thermo Fisher Scientific) according to the manufacturer's protocol. The Torrent Suite Software v5.2.2, (Thermo Fisher Scientific) and an in-house developed software Variant Explorer v2 were used for data analysis and interpretation.

Whole exome sequencing {#S4}
----------------------

Normal and tumor tissue from 5 of the 6 PDTCs were subjected to whole exome sequencing (WES). FFPE-derived DNA (50 ng) of normal and tumor areas independently underwent exome capture using the SureSelect Human All Exon V6 kit from Agilent Technologies followed by 125-bp paired-end sequencing on an Illumina HiSeq 4000 sequencer. WES was performed at the McGill University and Génome Québec Innovation Centre (MUGQIC). Analysis methods are described in the [Supplementary methods](#SD1){ref-type="supplementary-material"}.

Sanger sequencing of the *DICER1* gene {#S5}
--------------------------------------

*DICER1* mutations were further validated by Sanger sequencing using *DICER1* transcript version ENST00000343455.7. Primers are available upon request. The quality of the amplified PCR product was evaluated by agarose gel electrophoresis. Then, bidirectional Sanger sequencing was performed using the BigDye Terminator Kit on ABI3730 (Thermo Fisher Scientific, Waltham, Maryland, USA).

mRNA analysis of the *DICER1* germline variant {#S6}
----------------------------------------------

RNA was reverse transcribed into cDNA using SuperScriptIII first-strand cDNA synthesis (Thermo Fisher Scientific, Waltham, MA). *DICER1* transcript NM_177438 was used to design cDNA-specific PCR primers for the exon 6-exon 7 boundaries as well as for the c.G5437A; p.E1813K mutation. Presence of a modified transcript and zygosity at the cDNA level in tumor--derived cDNA was tested using PCR followed by Sanger sequencing. Primers are available upon request.

Results {#S7}
=======

Clinical and pathologic features {#S8}
--------------------------------

The clinical and pathologic features of the 6 PDTC cases in our series are summarized in [Table 1](#T1){ref-type="table"}. The age of patients ranged from 14 to 19 years and the female to male ratio was 2:1. One patient (Case 1) had a history of prior radiation to the thyroid at the age of 4 months for a right neck cavernous hemangioma associated with Kasabach-Merritt syndrome (coagulopathy) that was refractory to medical management and embolization. None of the other patients had a history of prior radiation and no patient had a history of other cancers. No patient had a personal or family history of DICER1 syndrome associated tumors or other features of DICER1 syndrome. Case 1 had a non-immediate family history of "bone cancer" and Case 2 had a non-immediate family history of esophageal and breast cancer on the maternal side (paternal family history was not available in this case). Family history was not available for Cases 3, 5 and 6.

Of 5 patients with clinical follow-up available, 3 developed distant metastases and experienced a rapidly fatal clinical course (survival of 8 months to 2 years). Two other patients were alive with no disease 3-4 years after diagnosis.

All patients underwent total thyroidectomy. Pathology examination revealed large tumors ranging in size from 3.1 to 9.0 cm. Microscopically, architectural growth patterns ranged from solid and insular to trabecular ([Fig. 1](#F1){ref-type="fig"}). Individual tumor cells had reduced amounts of cytoplasm, with relatively uniform nuclei and either dark or more vesicular chromatin. Mitotic activity was high in all tumors, ranging from 9 to 40 mitoses per 10 high power fields. Necrosis was identified in 5 of the 6 cases.

A definitive well-differentiated cancer component was observed in 3 tumors (Cases 3, 4 and 6) ([Fig. 2](#F2){ref-type="fig"}). In Case 3, the PDTC was present as a focus within an encapsulated follicular variant of papillary thyroid carcinoma with capsular and lymphovascular invasion. Case 5 had only rare neoplastic microfollicles. Cases 1 and 2 were entirely poorly differentiated with no well-differentiated component found. Immunohistochemistry confirmed thyroid origin in these cases.

Lymph node metastases were present in 3 tumors (Case 1, 3 and 5). In Case 1 and 5, the nodal disease was extensive. Case 1 had 8 positive lymph nodes, in addition to a group of matted lymph nodes, with extensive extranodal extension in the lateral neck and upper mediastinum. The largest lymph node metastasis as well as the matted group of lymph nodes both measured 4 cm in greatest dimension. Case 5 had 45 lymph node metastases involving the central, right and left lateral neck compartments. Extranodal extension was present. The size of the largest metastasis was 11 cm. In contrast, only one of two perithyroidal lymph nodes contained a less than 1 mm metastasis (highlighted by a cytokeratin immunostain) in Case 3.

The 3 tumors associated with patient death (Cases 1, 2 and 5) shared common features. They were of a large size (7.5-9.0 cm) and all showed lymphovascular invasion, extrathyroidal extension, and positive resection margins ([Fig. 1](#F1){ref-type="fig"}). None of these tumors revealed a definitive well-differentiated cancer component.

Targeted and whole exome sequencing analyses {#S9}
--------------------------------------------

Targeted next generation sequencing (Thyroseq v3) revealed *DICER1* mutations in 5 of 6 tumors; all were "hotspot" mutations located at codons 1705, 1709, 1713, and 1813 (x2) of exons 24-25, coding for the metal binding sites of the RNase IIIb domain of the protein ([Table 2](#T2){ref-type="table"}). All mutations were confirmed by Sanger sequencing ([Fig. 3](#F3){ref-type="fig"}). One tumor contained a second somatic mutation in the *DICER1* gene. The mutations were confirmed to be somatic in origin by Sanger sequencing of paired non-tumor tissues available in 4 out of 5 cases.

The WES analysis was performed in 5 cases. It confirmed all *DICER1* hotspot mutations detected by targeted NGS, confirmed a second somatic *DICER1* mutation in Case 3 and identified a previously unrecognized loss of heterozygosity in Case 4 (further discussed below, [Table 2](#T2){ref-type="table"}). Furthermore, it also revealed that Case 2 possessed a germline *DICER1* pathogenic variant (see below and [Table 2](#T2){ref-type="table"}) which, therefore, established the diagnosis of DICER1 syndrome in 1 of the 5 cases. No *DICER1* mutations were found in Case 5 by WES, confirming the targeted NGS findings. WES analysis could not be performed in 1 case with a somatic *DICER1* mutation (Case 6) due to lack of non-tumor DNA.

The one germline mutation, found in Case 2, was at a cryptic splice site in intron 6 (c.T735-8G) and predicted to affect the splicing of the transcript. In cDNA, the exon 6- exon 7 boundary showed no indication of an aberrant transcript however, a prominent allelic imbalance at the c.G5437A;p.E1813K hotspot mutation locus in this case indicated expression on only 1 allele, suggesting a non-sense mediated decay of an aberrant transcript ([Fig. 4](#F4){ref-type="fig"}). Thus, the germline variant is provisionally classified as likely pathogenic, indicating that this patient had otherwise clinically inapparent DICER1 syndrome. In Case 4, in addition to the previous identified p.E1813Q hotspot mutation, ExomeAI detected allelic imbalance in chromosome 14 including the whole *DICER1* locus, indicating loss of heterozygosity (LOH) in the tumor ([Supplemental Fig. 1](#SD1){ref-type="supplementary-material"})^[@R33]^. No other common driver mutations or gene fusions characteristic of adult well-differentiated thyroid cancer or PDTC (*BRAF*, *RAS*, *TERT*, *RET/PTC* and other) were detected by Thyroseq v3 assay or WES.

The only other gene with alterations found in two or more cases was *ATM*. A somatic truncating mutation in *ATM*- c.583dupA;p.T195fs was found in Case 1. This case also harbored a germline heterozygous missense variant in *ERCC2*-c.G1606A;p.V536M that has been reported to have dominant negative activity in breast cancer^[@R34]^. In Case 4, LOH for the *ATM* gene was detected as well as a germline *ATM* variant (c.C146G;p.S49C) ([Supplemental Table 1](#SD2){ref-type="supplementary-material"}). However, this germline variant is not definitively pathogenic^[@R35]^. Additional germline and somatic alterations identified in single cases are shown in [Table 3](#T3){ref-type="table"} and [Supplemental Table 1](#SD2){ref-type="supplementary-material"}; germline alterations found by WES analysis of each case and predicted to be pathogenic are shown in [Supplemental Tables 2](#SD2){ref-type="supplementary-material"}-[6](#SD2){ref-type="supplementary-material"}. Coverage metrics for the WES analysis in each case are shown in [Supplemental Table 7](#SD2){ref-type="supplementary-material"}.

Discussion {#S10}
==========

In this study, we uncover the genetic mechanisms of pediatric PDTC and demonstrate that these tumors typically carry *DICER1* mutations and lack molecular alterations characteristic of PDTC in adults. Furthermore, we show that pediatric PDTC may represent a manifestation of DICER1 syndrome.

DICER1 plays a central role in RNA interference including in the processing of microRNAs, and thus has a broad impact on gene expression. Germline loss-of-function non-"hotspot" mutations, when accompanied by a second, somatic "hit" to *DICER1*, cause DICER1 syndrome, an inherited cancer syndrome with variable expressivity for which a "two-hit" model has been proposed^[@R36]^. "Hotspot" *DICER1* mutations affecting the metal binding sites of the RNase IIIb domain are nearly all somatic in origin, likely due to deleterious effects during development^[@R36],[@R37]^. Rarely, they may occur as germline mutations in non-tumorous tissues in a mosaic state, but in DICER1 syndrome, they occur as second "hits" in associated tumors^[@R36],[@R37]^. Patients with DICER1 syndrome may develop pleuropulmonary blastoma, cystic nephroma, nasal chondromesenchymal hamartoma, embryonal rhabdomyosarcoma and ovarian sex-cord stromal tumors, among other tumors types, often at a young age^[@R38],[@R39]^. Multinodular thyroid goiter is also a frequent finding in DICER1 syndrome; 75% of affected women and 17% of men develop multinodular disease by age 40^[@R40]^. The patients are also at elevated risk of developing differentiated thyroid neoplasms which uniformly have been reported to have an indolent clinical course^[@R40],[@R41]^. These differentiated thyroid cancers contain second-hit "hotspot" mutations in *DICER1*^[@R40],[@R42],[@R43]^.

Two PDTCs with *DICER1* mutations in patients with DICER1 syndrome were recently reported in the literature; however, upon review of the published scanned whole slides of the tumors, we found that they did not meet Turin diagnostic criteria for PDTC^[@R41]^. Furthermore, the 2 reported tumors had no high-risk pathologic features and behaved in a clinically indolent manner, which is more in keeping with differentiated thyroid carcinoma.

Outside of DICER1 syndrome, *DICER1* mutations are rare in thyroid neoplasms and, to date, have been found nearly exclusively in well-differentiated tumors (papillary thyroid carcinoma, follicular carcinoma and follicular adenoma)^[@R41],[@R44]-[@R48]^. Of note, somatic "hotspot" *DICER1* mutations may be more common in pediatric compared to adult differentiated thyroid tumors, seen in 10% of pediatric papillary thyroid carcinomas in one series^[@R47]^. All were "low-risk" tumors according to the American Thyroid Association (ATA) guidelines^[@R47],[@R49]^. Although usually mutually exclusive with other driver mutations, a rare example of papillary thyroid carcinoma with a new *WNK1-B4GALNT3* fusion that also harbored a *DICER1* "hotspot" mutation has been reported^[@R45]^.

Genetic analysis of pediatric PDTC, as defined by the Turin criteria, has not been previously reported. Here, we show that *DICER1* mutations define a rare group of thyroid carcinomas that are poorly differentiated, occur mainly in adolescents and may have more clinically aggressive behavior than the existing literature suggests. Although none of our patients had other clinical manifestations or family history of DICER1 syndrome, one patient was found to have a germline intronic likely pathogenic variant consistent with clinically inapparent DICER1 syndrome. This indicates a need for genetic counselling of children and adolescents with PDTC, as the tumor type may be the first manifestation of DICER1 syndrome in a subset of these patients. Two other PDTCs had biallelic inactivation of *DICER1*, in line with the "two-hit" model of *DICER1* inactivation in oncogenesis. Only 1 of the 6 pediatric PDTC in our series had no *DICER1* mutations.

Only one tumor with a *DICER1* mutation has previously been reported among over 80 adult PDTC sequenced using assays that include the *DICER1* gene^[@R29],[@R50],[@R51]^. This was a case of PDTC defined by Turin criteria in a 22-year-old woman with a p.E1813K *DICER1* mutation, reported by Landa et al (2016)^[@R29]^. This case, together with the cases in the current series, provide strong evidence that PDTC in young patients represent a genetically homogeneous group of tumors developing via molecular pathways different from adult PDTC. The latter commonly harbor initiating *BRAF* or *RAS* mutations, which are not found in pediatric PDTC ^[@R29],[@R50]^. Despite distinct origins, adult and pediatric PDTC may, however, share late genetic events. A *TP53* mutation was present in one pediatric PDTC, which, along with *TERT* promoter mutations, is a common late genetic event in adult PDTC^[@R29],[@R50]^. Two of the *DICER1*-mutated PDTCs in our series additionally harbored somatic alterations in *ATM*, a cell-cycle checkpoint and DNA repair response gene, as well as germline *ATM* variants, one of which is not definitely pathogenic. *ATM* mutations have been reported in 5-10% of adult PDTCs and anaplastic thyroid carcinomas but only in 1-2% of differentiated thyroid carcinomas, suggesting that *ATM* mutations may represent another late molecular alteration in PDTC seen in both pediatric and adult tumors^[@R29],[@R46]^.

An important feature of the pediatric PDTCs in our series was the observed aggressive clinical behavior with a rapidly fatal clinical course (≤ 2 years) in 3 of our patients. Our review of the literature yielded 27 patients with PDTC that were ≤ 21 years of age ([Supplemental Table 8](#SD1){ref-type="supplementary-material"})^[@R8]-[@R28]^. Scanned slides from 2 tumors were available for review and indicated that these 2 cases did not meet Turin criteria for the diagnosis of PDTC^[@R41]^. These were excluded, leaving 25 cases. Most patients were adolescents, with only a few PDTCs occurring in children \< 10 years of age. Of 20 patients with clinical follow-up available, only 3 died of disease and 1 was alive with disease at last follow-up^[@R9],[@R14],[@R23],[@R26]^. Four patients were alive but the disease status was not known, and the remaining 12 patients were alive and free of disease (overall survival of 85%)^[@R8]-[@R15],[@R17],[@R19]-[@R21]^. The majority of cases reported in the literature predated the publication of the Turin diagnostic criteria in 2007^[@R4]^. An attempt was made to apply Turin criteria to all cases in the literature, but definitive confirmation of Turin criteria was possible in only 4 tumors, 3 of which had clinical follow-up information available^[@R14],[@R21],[@R22]^. Combining these 3 cases with 5 patients with clinical follow-up in the current series, 4 of 8 (50%) pediatric patients with PDTC defined by Turin criteria died of disease^[@R14],[@R21],[@R22],[@R28]^. Although the number of patients remain relatively small, these findings suggest that (i) the outcomes for pediatric PDTC may be worse than the existing literature suggests, and (ii) the overall survival of children with PDTC may be more in line with that of adults.

Prognostic features of pediatric PDTC are difficult to ascertain from our small number of cases. However, it is of interest to note that the 2 patients in our series with clinical follow-up who are alive and free of disease had more localized disease with no extrathyroidal extension and negative margins of resection. Furthermore, these tumors had a component of well-differentiated papillary thyroid carcinoma. One of the 2 cases showed tumor encapsulation, a feature that has been associated with a better prognosis in adults who have high-grade thyroid malignancies^[@R52]^. Evaluation of these characteristics in a larger number of pediatric PDTC may yield more definitive prognostic information.

Thyroid hyperplasia and neoplasia represent the most common phenotype in individuals with germline *DICER1* mutations; 75% of women and 17% of men have multinodular goiter (nodular hyperplasia) and/or removal of the thyroid by age 40^[@R40]^. Germline mutation carriers have a 16-18 fold increased risk for thyroid cancer compared with the general population^[@R40]^. Overall, previously reported *DICER1*-mutated thyroid carcinomas (both those with germline and somatic-only mutations) have nearly universally behaved in an indolent manner. The exception was a recent case report of a carcinosarcoma (anaplastic thyroid carcinoma with heterologous elements) that harbored an E1705K *DICER1* hotspot mutation in a tumor from a 45-year-old woman who died of disease after 4 months^[@R53]^. Our findings and this case suggest that *DICER1*-mutated differentiated thyroid tumors may be at risk for high-grade transformation, although this is likely an uncommon event. Further evidence of the potential for high-grade transformation from a differentiated thyroid carcinoma is the occurrence of PDTC in association with papillary thyroid carcinoma in 3 of our cases. This report demonstrates that the thyroid gland can express the full spectrum of neoplastic pathology from benign, often cystic, hyperplasias to poorly differentiated aggressive cancers seen in the other more fully described *DICER1*-associated neoplasms in the lung, ovary and kidney. As with these other organs, it appears that additional genetic events, beyond the biallelic combination of one *DICER1* loss of function and a "hotspot" mutation, may be necessary for high-grade transformation to take place. For lung and kidney, the most common additional genetic event associated with high-grade transformation is mutations and/or loss of *TP53*, seen in one of the five *DICER1*-associated PDTCs tested in this study^[@R54]-[@R56]^.

In summary, PDTC of childhood and adolescence is very rare and a historical lack of uniform diagnostic criteria and molecular studies has hindered our understanding of its biology and behavior. Our findings indicate that they may represent a distinct tumor type genetically different from adult-onset PDTC that is strongly associated with *DICER1* mutations and may herald DICER1 syndrome in a subset. The clinically aggressive behavior of these tumors contrasts sharply with the indolent nature of most thyroid tumors with *DICER1* mutations reported to date.

Supplementary Material {#SM1}
======================

This work was funded by the CIHR Foundation Grant FDN-148390 to W.D.F. and the National Institutes of Health grant CA181150 to Y.E.N. B.R. is a Young Investigator from the ALSF and the Mina Neri Foundation for Childhood Cancer.

Disclosure/Conflict of Interest

Y.E.N. owns intellectual property and receives royalties related to ThyroSeq. T.J.G. is a Consultant for Interspace Diagnostics. All other authors have nothing to disclose.

![Representative routine hematoxylin and eosin stained images of pediatric poorly differentiated thyroid carcinomas showing solid (A), insular (C) and trabecular (E) growth patterns. Mitotic activity (A) and necrosis (C) are present. Extrathyroidal extension with strap muscle invasion (B), vascular invasion (D) and positive margins (F) in Case 1. Only the 3 lethal cases showed extrathyroidal extension and positive margins, whereas lymphovascular invasion was present in all cases.](nihms-1547622-f0001){#F1}

![Both Case 3 and Case 6 showed poorly differentiated thyroid carcinomas arising in encapsulated follicular variant of papillary thyroid carcinoma. In Case 3 (A), the poorly differentiated component was focal (top right), whereas in Case 6 (B), it was extensive. Transition zones between papillary thyroid carcinoma and the poorly differentiated component are shown for Case 3 (C) and Case 6 (D). Case 3 was completely encapsulated but showed lymphovascular invasion (E). Case 6 showed capsular invasion (F) in addition to lymphovascular invasion.](nihms-1547622-f0002){#F2}

![RNase IIIb and non-RNase IIIb domain *DICER1* somatic mutations. RNase IIIb domain mutations in Cases 1-4 and 6 (A-E): A) Electropherogram of a G\>T substitution at c.5137 resulting in a D1713Y missense mutation (Case 1) B) Electropherogram of a G\>A substitution at c.5437 leading to an E1813K missense mutation (Case 2). C) Electropherogram of a G\>A substitution at c.5125 causing a D1709N missense mutation (Case 3). D) Electropherogram of a G\>C substitution at c.5437 causing an E1813Q missense mutation and loss of heterozygosity (Case 4). E): Electropherogram of a G\>A substitution at c.5113 causing an E1705K missense mutation (Case 6). Non-RNase IIIb domain *DICER1* mutation in Case 3: F) Electropherogram of an A duplication at c.3627 resulting in a frameshift mutation causing p.P1210Tfs\*25.](nihms-1547622-f0003){#F3}

![A) Chromatogram (upper) showing the location of the wild-type splice acceptor site before exon 7 in DNA from a control. Chromatogram (lower) showing the variant c.735-8T\>G (asterisk) and cryptic new acceptor splice site in DNA from Case 2. Black bold with underlined lettering shows the WT base. Bold red lettering shows the altered base. Blue arrow points to the wildtype splice acceptor and red arrow indicates the location of the new cryptic acceptor site. B) Schematic representation of the expected protein with an intact exon 7 acceptor splice site compared to the mutated c.735-8T\>G acceptor splice site. The red lines represent the aberrant splicing which retains 7bp from intron 6 and would be predicated to lead to a premature stop codon (red asterisk). If an aberrant transcript is present triggering its degradation by nonsense-mediated mRNA decay, no abnormal transcript would be detected in cDNA and the junction between Exon 6 and Exon 7 appeared to be intact. In the figure, upper chromatogram shows a wildtype junction between exons 6 and 7 in cDNA from case 4. Lower chromatogram shows allelic imbalance in exon 25 at position, c.5437G\>A, p.E1813K in cDNA. In this scenario, chromatograms depicting the presence of the hotspot mutation and a wildtype splicing in cDNA suggests 1) that an aberrant transcript has been degraded and only the allele with the c.5437G\>A, p.E1813K is retained and 2) the two variants are *in trans*. Yellow represents the DexD/H helicase domain. Blue represents the amino acids not belonging to a specific known domain.](nihms-1547622-f0004){#F4}

###### 

Clinical and pathologic features of pediatric poorly differentiated thyroid carcinoma

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case\   Patient\   Sex   Prior\      Differentiated\       Tumor\   Mitosis\   Necrosis   TG/\     LVI   ETE   Margin   LN\    Distant\            Patient\
  \#      age\             radiation   component             size\    (per 10\              TTF-1\                        mets   mets                Survival\
          (yrs.)                                             (cm)     HPF)                  IHC                                                      (mo)
  ------- ---------- ----- ----------- --------------------- -------- ---------- ---------- -------- ----- ----- -------- ------ ------------------- ---------------
  **1**   19         F     \+          No                    7.5      40         \+         +/+      \+    \+    \+       \+     Lung/brain          DOD ([@R24])

  **2**   17         M     −           No                    9.0      37         \+         +/+      \+    \+    \+       −      Lung/finger/scalp   DOD ([@R8])

  **3**   14         F     −           Encapsulated FV PTC   6.4      10         −          NA       \+    −     −        \+     −                   AWOD ([@R53])

  **4**   17         F     −           PTC                   3.1      22         \+         +/+      \+    −     −        −      −                   AWOD ([@R36])

  **5**   16         M     −           Rare microfollicles   \>7.5    9          \+         −/+      \+    \+    \+       \+     Lung                DOD ([@R10])

  **6**   14         F     −           Encapsulated FV PTC   5.0      21         \+         +/+      \+    −     −        −      −                   NA
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

FV PTC follicular variant papillary thyroid carcinoma; HPF high power field; TG thyroglobulin; TTF-1 thyroid transcription factor-1; NA not available; LVI lymphovascular invasion; ETE extrathyroidal extension; LN lymph node; mets metastases; mo months; DOD dead of disease; AWOD alive without disease

###### 

*DICER1* pathogenic variants in pediatric poorly differentiated thyroid carcinoma

  ------------------------------------------------------------------------------------------
  Case\   Somatic mutations\                         Germline mutation\    Other *DICER1*\
  \#      (VAF)                                      (VAF)                 alterations
  ------- ------------------------------------------ --------------------- -----------------
  **1**   p.1713Y(108/242)                           \-                    \-

  **2**   p.E1813K (71/219)                          c.735-8T\>G (41/69)   \-

  **3**   \#1 p.D1709N (78/210)\                     \-                    \-
          \#2 p.I1209fs (28/89)                                            

  **4**   p.E1813Q (156/163)                         \-                    LOH

  **5**   \-                                         \-                    \-

  **6**   p.E1705K[\*](#TFN3){ref-type="table-fn"}   NA                    \-
  ------------------------------------------------------------------------------------------

VAF Variant allele frequency shown in number of reads of alternate allele over total number of reads; NA not available; LOH loss of heterozygosity

Sample 6 was not subjected to WES so there is no VAF to report

###### 

Somatic mutations in other genes in the MSKCC-Impact panel (468 genes)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene     Case   Mutation                            Oncogenic\                COSMIC\                 VAF       SIFT          Poly\     Mutation\   Revel   MCAP     CADD
                                                      Classification\           ID                                              phen2     Taster                       
                                                      (CGI)                                                                                                            
  -------- ------ ----------------------------------- ------------------------- ----------------------- --------- ------------- --------- ----------- ------- -------- ------
  ATM      1      c.583dupA; p.T195fs                 Predicted Driver Tier 1   NA                      24/31     NA            NA        NA          NA      NA       NA

  CDC73    1      c.1013delA; p.Q338fs                Predicted Driver Tier 1   NA                      57/138    NA            NA        NA          NA      NA       NA

  MAP2K2   2      c.C383G; p.P128R                    Predicted Driver Tier 1   NA                      86/322    0,1.00,D      1.0,D     1.0,D       0.916   0.693    26.8

  RBM10    2      c.C2065T; p.R689C                   Predicted Driver Tier 1   COSM1315532             35/154    0,1.00,D      1.0,D     1.0,D       0.466   0.864    34

  ARID1A   2      c.5624_5625insCCCTGCCC; p.P1875fs   Predicted Driver Tier 1   NA                      73/284    NA            NA        NA          NA      NA       NA

  FLT3     2      c.G854T; p.W285L                    Predicted Driver Tier 1   NA                      30/115    0.22,0.78,T   0.737,P   0.967,D     0.47    0.0465   26.9

  EGFR     4      c.C2506G; p.R836G                   Predicted Driver Tier 1   NA                      32/162    0,1.00,D      1.0,D     1.0,D       0.856   0.289    34

  TP53     4      c.G631T; p.E211X                    Predicted Driver Tier 1   COSM11078, COSM308326   129/136   NA            NA        NA          NA      NA       35
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VAF variant allele frequency shown in number of reads of alternate allele over total number of reads; D damaging; B benign, P probably damaging, T tolerated, NA not applicable

DNA was amplified with primers flanking from exon 2 to exon 27 ([Supplemental Table 1](#SD2){ref-type="supplementary-material"})
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